The post Superstate Raises $82.5M to Expand Onchain IPOs and Fundraising appeared on BitcoinEthereumNews.com. Financial technology and tokenization company SuperstateThe post Superstate Raises $82.5M to Expand Onchain IPOs and Fundraising appeared on BitcoinEthereumNews.com. Financial technology and tokenization company Superstate

Superstate Raises $82.5M to Expand Onchain IPOs and Fundraising

Financial technology and tokenization company Superstate has raised $82.5 million in a Series B round as it pushes deeper into onchain capital markets, aiming to modernize the way companies raise money and go public using blockchain.

The round was led by Bain Capital Crypto and Distributed Global, with participation from Haun Ventures, Brevan Howard Digital, Galaxy Digital, Bullish, ParaFi and several other crypto-focused investors, according to a press release shared with Cointelegraph.

“This year, tokenization will catalyze the transformation of capital markets,” said Robert Leshner, CEO of Superstate. “We’re grateful to our partners that allow us to grow our best-in-class team, products, and ambitions,” he added.

According to its website, Superstate currently manages more than $1.23 billion in assets across two tokenized funds. The bulk of that capital sits in the US Government Securities Fund (USTB), which holds about $794.6 million in AUM and offers a yield of 3.52%, while the Crypto Carry Fund (USCC) accounts for roughly $441.9 million with a higher yield of 5.58%.

Superstate’s supported equities. Source: Superstate website

Related: New protocol targets redemption delays in $20B tokenized market

Superstate to scale onchain issuance layer

Superstate plans to use the new capital to expand beyond its initial Treasury-backed offerings and build a full onchain issuance layer for United States Securities and Exchange Commission (SEC)-registered equities on Ethereum (ETH) and Solana (SOL).

The New York–based firm also revealed plans to expand its transfer agent platform and Opening Bell, a platform for tokenized public equities, to support more issuers, workflows and distribution channels.

In late 2025, Superstate expanded its Opening Bell platform to support Direct Issuance Programs, allowing public companies to issue and sell digital shares directly to investors on public blockchains.

As an SEC-registered transfer agent, Superstate manages issuance, settlement and ownership records onchain, allowing trades and ownership updates in real time. The company says this replaces slow, manual processes and makes fundraising and IPOs more efficient while staying compliant.

Related: Goldman Sachs, BNY to offer tokenized money market funds for clients

Tokenized US Treasurys surge 50x

As Cointelegraph reported, tokenized US Treasury products have become one of the fastest-growing areas in the real-world asset market, expanding nearly 50-fold in under two years as institutions seek onchain yield.

The sector’s market capitalization rose from less thn $200 million in early 2024 to nearly $7 billion by late 2025. BlackRock’s USD Institutional Digital Liquidity Fund (BUIDL) led the market, accumulating close to $2 billion in assets by offering tokenized exposure to short-term Treasurys with daily yield and onchain settlement.

Magazine: How crypto laws changed in 2025 — and how they’ll change in 2026

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Source: https://cointelegraph.com/news/superstate-raises-82m-tokenized-capital-markets?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26